Davies, T. W.
Kelly, E.
van Gassel, R. J. J.
van de Poll, M. C. G.
Gunst, J.
Casaer, M. P.
Christopher, K. B.
Preiser, J. C.
Hill, A.
Gundogan, K.
Reintam-Blaser, A.
Rousseau, A.-F.
Hodgson, C.
Needham, D. M.
Schaller, S. J.
McClelland, T.
Pilkington, J. J.
Sevin, C. M.
Wischmeyer, P. E.
Lee, Z. Y.
Govil, D.
Chapple, L.
Denehy, L.
Montejo-González, J. C.
Taylor, B.
Bear, D. E.
Pearse, R. M.
McNelly, A.
Prowle, J.
Puthucheary, Z. A.
Funding for this research was provided by:
National Institute of Health Research (NIHR) Academic Clinical Fellowship Award Programme (2021-19-009)
National Institute of Health Research (NIHR) Pre-Doctoral Clinical Academic Fellowship Award Programme (NIHR302695)
Article History
Received: 14 September 2023
Accepted: 9 November 2023
First Online: 20 November 2023
Declarations
:
: Not applicable.
: Not applicable.
: JCP is an editor of Critical Care<i>.</i> ZP has received honoraria for consultancy and/or speaker fees from Nestle, Fresenius Kabi, Nutricia, Baxter and Faraday Pharmaceuticals, and research and educational grants from Nestle and Baxter. ARB has received honoraria for consultancy and/or speaker fees from Nestlé, Fresenius Kabi, VIPUN Medical and Nutricia. SJS received grants and non-financial support from Reactive Robotics GmbH (Munich, Germany), ASP GmbH (Attendorn, Germany), STIMIT AG (Biel, Switzerland), ESICM (Geneva, Switzerland), grants, personal fees, and non-financial support from Fresenius Kabi Deutschland GmbH (Bad Homburg, Germany), grants from the Innovations fund of The Federal Joint Committee (G-BA), personal fees from Springer Verlag GmbH (Vienna, Austria) for educational purposes and Advanz Pharma GmbH (Bielefeld, Germany), non-financial support from national and international societies (and their congress organisers) in the field of anaesthesiology and intensive care medicine, outside the submitted work. SJS holds stocks in small amounts from Alphabet Inc., Bayer AG, and Siemens AG; these holdings have not affected any decisions regarding his research or this study. AH’s position is currently supported by a stipend from the Medical Faculty RWTH Aachen “Habilitationsstipendium”. Within the last 36 months AH received lecture and travel fees from Fresenius Kabi Germany and Baxter and grants for investigator initiated trials from the DFG, Fresenius Kabi Germany, Lotte & John Hecht Memorial Foundation and Pascoe. None of the disclosed financial relationships may be perceived as inappropriately influencing AH’s contribution to this project or this manuscript. MVP received research funding from Fresenius-Kabi and Nutricia Research, speakers fees from Nutricia. MVP is the principal investigator of the PRECISe trial, which uses a COS for resp failure by DN. MPC receives funding from the Research Foundation Flanders (FWO) (Grant No. 1832817N) and Onderzoeksraad, KU Leuven (Grant No. C24/17/070) and the Private Charity Organization “Help Brandwonden Kids”. DEB has received speaker fees from Baxter Healthcare and has received research grant funding from Nutricia Ltd. RMP has received honoraria and/or research grants from Edwards Lifesciences and Intersurgical UK. All other authors declare that they have no competing interests<i>.</i>